Abstract
Little is known about optimal surveillance schedules for patients who undergo repeat ablation after the recurrence of hepatocellular carcinoma (HCC) initially treated with surgical resection or ablation (initially recurrent hepatocellular carcinoma [irHCC]). Given the low 5-year recurrence-free survival rates of 17.3%–30.2% among patients undergoing ablation after irHCC (1,2), a predictive model would be greatly beneficial in balancing timely recurrence detection against excessive follow-up visits in this population.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
